HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.

Abstract
Alzheimer's disease (AD) is the most prevalent form of dementia with an estimated worldwide prevalence of over 30 million people, and its incidence is expected to increase dramatically with an increasing elderly population. Up until now, cerebrospinal fluid (CSF) has been the preferred sample to investigate central nervous system (CNS) disorders since its composition is directly related to metabolite production in the brain. In this work, a nontargeted metabolomic approach based on capillary electrophoresis-mass spectrometry (CE-MS) is developed to examine metabolic differences in CSF samples from subjects with different cognitive status related to AD progression. To do this, CSF samples from 85 subjects were obtained from patients with (i) subjective cognitive impairment (SCI, i.e. control group), (ii) mild cognitive impairment (MCI) which remained stable after a follow-up period of 2 years, (iii) MCI which progressed to AD within a 2-year time after the initial MCI diagnostic and, (iv) diagnosed AD. A prediction model for AD progression using multivariate statistical analysis based on CE-MS metabolomics of CSF samples was obtained using 73 CSF samples. Using our model, we were able to correctly classify 97-100% of the samples in the diagnostic groups. The prediction power was confirmed in a blind small test set of 12 CSF samples, reaching a 83% of diagnostic accuracy. The obtained predictive values were higher than those reported with classical CSF AD biomarkers (Aβ42 and tau) but need to be confirmed in larger samples cohorts. Choline, dimethylarginine, arginine, valine, proline, serine, histidine, creatine, carnitine, and suberylglycine were identified as possible disease progression biomarkers. Our results suggest that CE-MS metabolomics of CSF samples can be a useful tool to predict AD progression.
AuthorsClara Ibáñez, Carolina Simó, Pedro J Martín-Álvarez, Miia Kivipelto, Bengt Winblad, Angel Cedazo-Mínguez, Alejandro Cifuentes
JournalAnalytical chemistry (Anal Chem) Vol. 84 Issue 20 Pg. 8532-40 (Oct 16 2012) ISSN: 1520-6882 [Electronic] United States
PMID22967182 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Alzheimer Disease (cerebrospinal fluid, diagnosis, metabolism, pathology)
  • Disease Progression
  • Electrophoresis, Capillary (methods)
  • Follow-Up Studies
  • Humans
  • Mass Spectrometry (methods)
  • Metabolomics (methods)
  • Models, Biological
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: